AIDS Exclusive Interview: Latest Advances and Challenges in Long-Acting HIV Prevention Technologies

AIDS Exclusive Interview: Latest Advances and Challenges in Long-Acting HIV Prevention Technologies

At the AIDS 2024 Conference, Dr. Albert Liu from the University of California, San Francisco, delivered a keynote presentation on the latest developments in long-acting HIV prevention technologies. Following his talk, he participated in an exclusive interview with Infectious Diseases Frontier. Dr. Liu highlighted that the field of HIV prevention is currently undergoing exciting transformations. Long-acting drugs, such as bimonthly injections and monthly vaginal rings, have already been approved, significantly improving prevention outcomes and reducing patient burden. Additionally, other technologies in development, such as long-acting tablets, HIV implants, and broadly neutralizing antibodies, show immense potential. However, cost and accessibility remain key challenges to widespread adoption. Future research must focus on the safety, efficacy, and community implementation strategies of these technologies while also simplifying delivery processes to ensure these innovations benefit a broader population and advance HIV prevention efforts.
Spatially resolved transcriptomics: advances and applications

Spatially resolved transcriptomics: advances and applications

In January 2023, a review by Professor Tao Cheng  from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Blood Science . The title of the study is "Spatially resolved transcriptomics: advances and applications". This review summarizes the interplay between technological innovation and biological discovery continues to push the boundaries of what was previously imaginable, translating our approach to complex biological systems and disease pathology.
World’s First Case! Extremely Rare Blood Type Discovered

World’s First Case! Extremely Rare Blood Type Discovered

Recently, the Blood Transfusion Department at The First Hospital of Handan in Hebei Province identified an extremely rare B subtype blood type. This blood type results from a heterozygous mutation in exon 7 of the ABO allele, specifically c.449A>G, making it even rarer than the well-known "Panda Blood" (Rh-negative blood).
Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion

Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion

In the evolving field of hematology and oncology, addressing acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is crucial. A recent study highlighting AML relapse as pericardial effusion marks significant progress in this area. Led by Professor Sizhou Feng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, this research underscores innovative diagnostic and therapeutic strategies.
Sequential Treatment Escalation Improves Survival in Patients with Waldenstrom Macroglobulinemia

Sequential Treatment Escalation Improves Survival in Patients with Waldenstrom Macroglobulinemia

In the dynamic field of hematology and oncology, finding effective treatments for Waldenstrom macroglobulinemia (WM) is crucial. A recent study led by Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,  has made significant strides in this area. This research analyzed first- and second-line therapies in 377 patients with WM, demonstrating that sequential treatment escalation markedly improves survival rates. By transitioning from cytotoxic drugs to rituximab, bortezomib, or Bruton tyrosine kinase inhibitors, patients saw significant benefits. These findings, presented at a major medical conference, underscore the collaborative effort and innovation driving progress in hematology and improving patient outcomes.
Sequential Infusion of Two Different Chimeric Antigen Receptor T Cells: Induction of a Deep and Durable Remission

Sequential Infusion of Two Different Chimeric Antigen Receptor T Cells: Induction of a Deep and Durable Remission

In the dynamic field of hematology and oncology, the development of innovative treatments for challenging conditions such as relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) remains a critical priority. In this commentary, the recent phase 2 clinical trial investigating the efficacy of sequential CD19 and CD22 CAR T-cell therapies represents a significant advancement in the therapeutic landscape. Professor Kailin Xu from the Affiliated Hospital of Xuzhou Medical University, along with esteemed colleagues, offers new hope for patients facing this aggressive malignancy. He highlighted the findings of this pioneering research, published in the Lancet Oncology, which reported not only the potential of sequential CD19 and CD22 CAR T-cell therapy as a viable treatment option, but also the collaborative effort and expertise that exemplify the spirit of innovation in the field.
JOH丨Impact of Pre-Transplant Immunotherapy on Post-Transplant Outcomes in Liver Cancer

JOH丨Impact of Pre-Transplant Immunotherapy on Post-Transplant Outcomes in Liver Cancer

The Journal of Hepatology (JOH) recently published an online systematic review and individual patient data meta-analysis conducted by Cedars-Sinai Medical Center in Los Angeles. The study investigates the impact of using immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) before liver transplantation on various key clinical outcomes post-transplantation. The findings reveal that while ICIs treatment may increase the risk of post-transplant rejection, the overall risk remains manageable, with patient age and ICI clearance time being closely related to rejection risk. This study provides valuable clinical data to support the use of ICIs before liver transplantation, offering new insights and directions for research and clinical practice in this area.
JOH丨Impact of HBV DNA Integration on Diagnosis, Treatment, and Prognosis of Chronic Hepatitis B

JOH丨Impact of HBV DNA Integration on Diagnosis, Treatment, and Prognosis of Chronic Hepatitis B

HBV infection is a global public health issue, with its chronic progression leading to severe liver diseases such as chronic hepatitis B (CHB), cirrhosis, and hepatocellular carcinoma (HCC). In recent years, the phenomenon of HBV DNA integrating into the host genome has garnered widespread attention as it unveils new mechanisms of HBV pathogenesis and significantly impacts the diagnosis, treatment, and prognosis of HBV-related diseases. Recently, Dr. Fabien Zoulim from Lyon Hepatology Institute, France, published a comprehensive review article in the Journal of Hepatology (JOH), detailing the mechanisms of HBV DNA integration, its impact on liver disease progression, and its implications for the functional cure of CHB. This review aims to provide new perspectives and methods for the prevention and treatment of CHB
Pre-TIPS Assessment of Liver-Related Vascular Morphology Can Predict Overt Hepatic Encephalopathy

Pre-TIPS Assessment of Liver-Related Vascular Morphology Can Predict Overt Hepatic Encephalopathy

Portal hypertension can lead to complications such as variceal bleeding and ascites. Transjugular intrahepatic portosystemic shunt (TIPS) creates an artificial channel between the hepatic vein and portal vein to reduce portal pressure. TIPS is the only minimally invasive method that can reduce or even normalize portal pressure and is effective in controlling variceal bleeding and refractory ascites. However, American, Chinese, and European guidelines recommend endoscopic treatment, non-selective beta-blockers, and paracentesis as the first-line treatments for variceal bleeding and ascites related to portal hypertension, with TIPS recommended as an alternative treatment. One of the main reasons is that TIPS can induce overt hepatic encephalopathy (HE), with an incidence rate of 10% to 50%, negatively affecting patients' quality of life and increasing mortality. Even with multiple treatments, the recurrence rate of HE remains high. These factors make predicting the risk of overt HE crucial for determining patient eligibility for TIPS. Recently, a study by Dr. Ligong Lu from Zhuhai People's Hospital, published in Hepatology International, explored the feasibility of using liver vascular assessments to predict HE, providing evidence to support the selection of suitable patients for TIPS treatment.
AIDS 2024丨Unique Changes in the Gut Virome of HIV-Exposed Uninfected Infants

AIDS 2024丨Unique Changes in the Gut Virome of HIV-Exposed Uninfected Infants

At the 25th International AIDS Conference (AIDS 2024) in Munich, Germany, a study on the impact of HIV on the gut virome of children garnered significant attention. This research was conducted by scientists from the University of Washington in Seattle, Seattle Children's Hospital, and the University of Cape Town in South Africa. The study revealed unique changes in the gut virome of HIV-exposed uninfected (HEU) infants born to HIV-infected mothers.